Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with Idarubicin and Cytarabine in MDS and AML
NCT00831766Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2009
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Moffitt Cancer Center. Started Jun 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00831766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831766.